Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 15/20 | 0.54 |
| ▸ | EGFR | P00533 | 1/20 | 0.54 |
| ▸ | RAF1 | P04049 | 1/20 | 0.54 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.54 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.54 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.54 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.54 |
| ▸ | GSK3B | P49841 | 1/20 | 0.54 |
| ▸ | MAPK13 | O15264 | 7/20 | 0.50 |
| ▸ | MAPK12 | P53778 | 7/20 | 0.50 |
| ▸ | MAPK11 | Q15759 | 7/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 2/20 | 0.42 |
| ▸ | JAK3 | P52333 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5385808 | 0.92 | MAPK14 (0.58) | MAPK14EGFRRAF1ADORA3ADORA2A | |
| SCHEMBL5394985 | 0.88 | MAPK14 (0.53) | MAPK14EGFRRAF1ADORA3ADORA2A | |
| SCHEMBL5387950 | 0.86 | MAPK14 (0.56) | MAPK14EGFRRAF1ADORA3ADORA2A | |
| SCHEMBL5378933 | 0.82 | MAPK14 (0.58) | MAPK14EGFRRAF1ADORA3ADORA2A | |
| SCHEMBL5379033 | 0.82 | MAPK14 (0.58) | MAPK14EGFRRAF1ADORA3ADORA2A | |
| SCHEMBL6489536 | 0.82 | MAPK14 (0.57) | MAPK14EGFRRAF1ADORA3ADORA2A | |
| SCHEMBL14592984 | 0.81 | MAPK14 (0.56) | MAPK14EGFRRAF1ADORA3ADORA2A | |
| SCHEMBL5393581 | 0.81 | MAPK14 (0.56) | MAPK14EGFRRAF1ADORA3ADORA2A | |
| SCHEMBL5378779 | 0.81 | MAPK14 (0.56) | MAPK14EGFRRAF1ADORA3ADORA2A | |
| SCHEMBL5382408 | 0.80 | MAPK14 (0.55) | MAPK14EGFRRAF1ADORA3ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7166597-B2 | Fused pyrazole derivatives being protein kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2007-01-23 | — | — | US | disclosed |
| US-7166597-B2 | Fused pyrazole derivatives being protein kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2007-01-23 | — | — | US | disclosed |
| US-7166597-B2 | Fused pyrazole derivatives being protein kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2007-01-23 | — | — | US | disclosed |
| EP-1311507-B1 | FUSED PYRAZOLE DERIVATIVES BEING PROTEIN KINASE INHIBITORS | GLAXO GROUP LTD (GB) | 2006-03-01 | — | — | EP | disclosed |
| US-20040053942-A1 | Fused pyrazole derivatives bieng protein kinase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2004-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053942-A1 | Fused pyrazole derivatives bieng protein kinase inhibitors | RAF1, SBK3, MAP3K3 | MAPK14 77/4885EGFR 786/4885RAF1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.